ARTICLE | Product Development
Alzheimer’s blood markers promise new era of clinical trials
Sensitive technologies could relieve dependence on imaging, but agreement on standards will be key
September 28, 2021 4:43 PM UTC
Amid growing acceptance of blood-based tests to diagnose Alzheimer’s disease, the assays are beginning to show their worth for monitoring treatment responses in trials, opening the door to greater understanding of the mechanism and duration of therapeutic effects.
“It’s really the blood tests that are revolutionizing the field,” Howard Fillit, founding executive director and CSO of the Alzheimer’s Drug Development Foundation (ADDF), told BioCentury...